N=30 | ||
Any grade | Grade 3–4 | |
Any treatment-related adverse event | 19 (63) | 11 (37) |
Rash | 5 (17) | 4 (13) |
Fever | 4 (13) | 0 |
Maculopapular rash | 4 (13) | 0 |
Lipase increased | 3 (10) | 3 (10) |
Anemia | 2 (7) | 1 (3) |
Fatigue | 2 (7) | 0 |
Hypothyroidism | 2 (7) | 0 |
Alanine aminotransferase increased | 2 (7) | 1 (3) |
Amylase increased | 2 (7) | 2 (7) |
Aspartate aminotransferase increased | 2 (7) | 1 (3) |
Blood alkaline phosphatase increased | 2 (7) | 0 |
Gamma-glutamyltransferase increased | 2 (7) | 2 (7) |
Infusion-related reaction | 2 (7) | 0 |
Eczema | 1 (3) | 1 (3) |
Lichenoid dermatitis | 1 (3) | 1 (3) |
Lip squamous cell carcinoma | 1 (3) | 1 (3) |
Seborrheic keratosis | 1 (3) | 1 (3) |
Skin lesions* | 2 (7) | 0 |
Keratoacanthoma | 2 (7) | 0 |
Data are n (%).
*Include MedDRA V.21.0 preferred terms squamous cell carcinoma of the skin, basal cell carcinoma, keratoacanthoma, hyperkeratosis, and actinic keratosis.